Retrospective study looking the the effect of anti-retroviral prophylaxis in patients who do not have active hepatitis B infection- with the premise that it influences anti-tumour immunity, pilot study completed locally.

Ultimately the study had a negative result: In both the Australian and Singapore cohorts addition of anti-retroviral either had no effect on survival or was associated with a poor prognosis, in contrast to the hypothesised favourable effect of this treatment on prognosis. This work was presented at Blood 2023 by Dr Elizabeth Smyth from Sir Charles Gairdner Hospital.